

Safety Communication

رسالة سلامة

Cases of structural valve deterioration insufficiency and early revision.

Device/ Product Description:	Bio-prosthetic aortic heart valves
Brand:	Trifecta / Trifecta GT
Affected product:	Models: TF-19A, TF-21A, TF23A, TF25A, TF-27A, TF-29A Models TFGT19A, TFGT-21A, TFGT-23A, TFGT-25A, TFGT-27A, TFGT-29A
Manufacturer:	Abbott
Problem:	Adverse incident reports relate to revision (explant or valve-in-valve repair) due to some form of structural valve deterioration (SVD). The most common reported problems were leaflet damage and/or valvular insufficiency along with a range of other associated concerns. Time to failure ranged from perioperative to 8 years, with approximately half occurring between 2 to 3 years post implant.
Recommendation /Actions:	<ul style="list-style-type: none"> • Make sure that this notice is reached to the end-users. • Read Abbott's Technical Bulletin, dated 13 January 2020, on the Trifecta/Trifecta GT bioprosthetic surgical aortic heart valve. • Note precautions regarding proper valve sizing and handling in accordance with the instructions for use (IFU): <ul style="list-style-type: none"> ○ Implantation of an inappropriately large bioprosthesis may result in stent deformation, valvular incompetence, and/or damage to the surrounding tissue ○ Do not oversize the valve ○ Do not bend the titanium valve stent. The titanium valve stent is not designed as a flexible stent. • Identify those patients implanted with a 1st generation Trifecta valve and consider implementing enhanced follow-up.

For more information, Please click [here](#).


If you think you had a problem with your device or a device your patient uses, please report the problem to SFDA through:

[NCMDR](#)

[Vigilance system](#)

19999 unified call center

Devices/Products photo:



Authorized Representative Details

AR name:	Medical Regulations Gate
Assigned Contact Person:	Abdulaziz Alqahtani
Mobile/Phone:	0506121295
Email:	ameen@mr-gate.com